Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Personalized Medicine and its Impact in the Clinic

Personalized Medicine and its Impact in the Clinic

Keynote Speakers

Klaus Pantel
Director, University Of Hamburg

Christof von Kalle
Head of Translational Oncology, German Cancer Research Center


At Personalized Medicine and its Impact in the Clinic, current and future laboratory developed tests will be examined with insight into the changing regulatory landscape. Biomarker identification and characterization will also be discussed, along with how companion diagnostics are validated, approved, reimbursed and marketed. This conference track is a great opportunity for talks between pharma & diagnostic companies, academic & institutional research, clinicians & industry stakeholders. 

The Personalized Medicine and its Impact in the Clinic track will run along side Genome Engineering in the Convention Centre adjacent to the BIOTECHNICA/LABVOLUTION  exhibition. Each track runs for two days and is broken down into four sessions. Delegates have the option to attend all tracks, single tracks, single days of a single track, or single sessions from 7-8 October 2015. In addition, all Personalized Medicine and its Impact in the Clinic and Genome Engineering delegates will also receive free access to the BIOTECHNICA/LABVOLUTION  exhibition and the ELA Advances in LabAutomation and Robotics conference.

With over 500 exhibitors and 12,000 visitors expected to attend BIOTECHNICA/LABVOLUTION, this will be a must attend meeting for all biotech researchers, developers and manufacturers. 

Agenda Topics

  • Cross-Omics Systems
  • Large Oncology & CNS Focus
  • NGS-Based Diagnostics
  • Regulatory, Reimbursement & HTA Updates

Sponsorship and Exhibition Opportunities

Exhibition Team,
+44 (0) 1206 501654

Distinguished Faculty

Ailish Higgins, Analyst, National Institute for Health and Care Excellence (NICE)
Ahmed Enayetallah, Associate Medical Director for Alzheimer’s Disease, Biogen Idec
Sherry Yang, Chief, National Clinical Target Validation Laboratory, National Cancer Institute
Samir Hanash, Director, University of Texas MD Anderson Cancer Center
Jeremy Segal, Director, University of Chicago
Arijit Chakravarty, Director, Takeda Pharmaceuticals Co Ltd
Reinhard Buettner, Director, University Hospital Cologne
Catherine Alix-Panabières, Director of the Laboratory of Rare Human Circulating Tumor Cells, University Medical Centre of Montpellier
Edith Schallmeiner, Global Team Director - NPT, Novartis
Theodora Katsila, Senior Research Scientist, University of Patras
Ryan Richardson, Vice President, Healthcare Investment Banking , J.P. Morgan

Corporate SponsorsWeb SponsorsOffical Journal PartnerNetworking
Drug Discovery WorldU-Networks